Pfizer Inc
PFENYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Aug 4, 2026Score 11/3056% above fair value
$30.52+0.57 (+1.90%)
Close on Oct 30, 2026Market cap $173.95BP/E 40.2Yield 5.64%
Pfizer Full-Year Revenue Guidance — Upper end by Quarter
Full-Year Revenue Guidance — Upper end ($M) ($M)
Pfizer Full-Year Revenue Guidance — Upper end: $62,500M in Q2 2026, down 2.3% from a year earlier.
Latest, Q2 2026
62,500
Period ended Jun 28, 2026
Change on a year earlier
-2.3%
64,000 in Q2 2025
History
29 quarters
Since Q1 2018
Sources
29
Documents cited below
Where the Q2 2026 figure comes from
“|| Revenues ($ in billions) Midpoint | $59.5 to $62.5 $61.0 | +$1.5 | -$1.0 | - | $60.5 to $62.5 $61.5”
Source: Form 8-K (Earnings / Guidance Release) (pfe-6282026xex99.htm, filed 2026-08-04) ↗
Reported in Form 8-K Full-Year Financial Guidance Tables.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Cite this data
StockData. (2026). Pfizer Full-Year Revenue Guidance — Upper end ($M), quarterly Q1 2018–Q2 2026 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/guid-rev-high
See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.